92501-87-6

Basic information

• Product Name: Methyl 4-(2-morpholin-4-yl-ethoxy)benzoate
• Synonyms: Methyl 4-(2-morpholin-4-yl-ethoxy)benzoate;methyl 4-(2-morpholinoethoxy)benzoate
• CAS NO: 92501-87-6
• Molecular Formula: C₁₄H₁₉NO₄
• Molecular Weight: 265.30496
• Mol File: 92501-87-6.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-(2-morpholin-4-yl-ethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(2-morpholin-4-yl-ethoxy)benzoate(92501-87-6)
• EPA Substance Registry System: Methyl 4-(2-morpholin-4-yl-ethoxy)benzoate(92501-87-6)

Safety Data

• Statements: 20/21/22-37/38-33
• Safety Statements: 7/8-26-36/37/39-45
• Hazardous Substances Data: 92501-87-6(Hazardous Substances Data)

Usage

Chemical Properties

Yellow liquid

Upstream product

• 622-40-2 2-(morpholin-4-yl)ethanol 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 5026-62-0 sodium methylparaben 
• 110-91-8 morpholine 
• 56850-91-0 methyl 4-(2-bromoethoxy)benzoate 
• 3240-94-6 N-(2-chlorethyl)morpholine 

Downstream Products

• 933824-17-0 C₃₂H₃₂N₂O₄ 
• 933824-20-5 C₃₄H₃₆N₂O₄ 
• 933824-19-2 C₃₂H₃₀N₄O₈ 
• 933824-18-1 C₃₂H₃₀Cl₂N₂O₄ 
• 134599-45-4 4-(2-morpholin-4-yl-ethoxy)-benzoic acid 

Relevant articles and documents

C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to C-3 novel triterpenone with C-17 reverse amide compounds of Formula (I); and pharmaceutically acceptable salts thereof, wherein ring Formula (II), R1, R2, R3, R4, R5, R6, R7, 'n' and 'm' are as defined in Formula (I). The invention also relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Influence of a Basic Side Chain on the Properties of Hypoxia-Selective Nitro Analogues of the Duocarmycins: Demonstration of Substantial Anticancer Activity in Combination with Irradiation or Chemotherapy

A new series of nitro analogues of the duocarmycins was prepared and evaluated for hypoxia-selective anticancer activity. The compounds incorporate 13 different amine-containing side chains designed to bind in the minor groove of DNA while spanning a wide range of base strength from pKa 9.64 to 5.24. The most favorable in vitro properties were associated with strongly basic side chains, but the greatest in vivo antitumor activity was found for compounds containing a weakly basic morpholine. This applies to single-agent activity and for activity in combination with irradiation or chemotherapy (gemcitabine or docetaxel). In combination with a single dose of γ irradiation 50 at 42 μmol/kg eliminated detectable clonogens in some SiHa cervical carcinoma xenografts, and in combination with gemcitabine using a well-tolerated multidose schedule, the same compound caused regression of all treated A2780 ovarian tumor xenografts. In the latter experiment, three of seven animals receiving the combination treatment were completely tumor free at day 100.

FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE

Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.